Go to Top

We discover and develop novel, "best-in-class" inhibitors of CYP17, a validated metalloenzyme involved in prostate cancer.

Partnering

Partnering

We value and wish to hear from creative parties who share our motivation to accelerate seviteronel development for the treatment of breast and prostate cancer. We also welcome inquiries from those who would like more information on our selective CYP17 lyase inhibitor pipeline.

To learn more about partnering opportunities with Innocrin, contact:

Charles Osborne

Chief Financial Officer

cosborne@innocrinpharma.com

Phone: 919-200-6635